Laurus Labs Ltd reported consolidated revenue from operations of ₹17.18 billion for the December quarter, alongside a net profit of ₹2.52 billion. The results highlight resilience in the company’s pharmaceutical and biotech segments, reflecting stable demand and operational efficiency despite industry challenges. Analysts view the performance as broadly in line with expectations.
Show moreStay Ahead – Explore Now! Biocon Seals The Deal: 98% Stake In Biocon Biologics Now Under Its Wing
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
